"""The development programme has been initiated and focused on
a vaccine candidate that integrates 3 different technologies:
*eTheRNA's proprietary Trimix technology:an mRNA-based vaccine
adjuvant that stimulates dendritic cells into avtivating a strong CD4
and CD8Tcell response.
*A combination of T cell epitopes from the virus brought together
on a single mRNA construct. For SARS-CoV-2 this will employ an
in-silico epitope prediction and design approach from EpiVax Inc. to
identify the target.
*An intranasal vaccine delivery platform using a nasal atomizer and
a proprietary formulation that delivers the mRNA to the nasal mucosa
and optimizes sxpression. One of the most promising formulation
candidates is being repurposed for clinical use in collaboration with
REPROCELL."""
>>13
リプロセルから開発ワクチンの詳細は発表されていませんが、
2020年3月24日で報道された英文記事の抜粋をご参考までに下記に
リピートしました。
"""The development programme has been initiated and focused on
a vaccine candidate that integrates 3 different technologies:
*eTheRNA's proprietary Trimix technology:an mRNA-based vaccine
adjuvant that stimulates dendritic cells into avtivating a strong CD4
and CD8Tcell response.
*A combination of T cell epitopes from the virus brought together
on a single mRNA construct. For SARS-CoV-2 this will employ an
in-silico epitope prediction and design approach from EpiVax Inc. to
identify the target.
*An intranasal vaccine delivery platform using a nasal atomizer and
a proprietary formulation that delivers the mRNA to the nasal mucosa
and optimizes sxpression. One of the most promising formulation
candidates is being repurposed for clinical use in collaboration with
REPROCELL."""